ZTS Stock Price Today (September 2026) — Zoetis Inc. Analysis & Key Metrics 2026-09-03
Zoetis Inc. (ZTS) is trading at $76.29, up 0.16% today (as of September 2026). The stock continues to show early recovery signs above the short-term average, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $96.00 (25.8% upside).
- Volatility remains elevated (27.19% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (-20.00% YoY) alongside significant competitive pressures.
ZTS Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Zoetis Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $39.54B
P/E Ratio
Forward P/E: 11.80
Revenue Growth
Year over Year
Analyst Target
+25.8% upside potential
Key Investor Questions About ZTS
What investors need to know before buying
Based on current market data, ZTS presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 50.16)
- Fundamentals say: Challenging (declining revenue trends)
ZTS's growth trajectory depends on its ability to expand within the Drug Manufacturers - Specialty & Generic sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - Specialty & Generic operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ZTS investors include debt exposure and competitive dynamics in the Drug Manufacturers - Specialty & Generic industry.
- $9.26B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - Specialty & Generic.
52-Week Trading Range
Over the past year, ZTS stock traded between $71.00 and $155.38—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 27.19% annualized volatility and β=0.66, the stock exhibits low sensitivity to market moves—making ZTS suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Is Zoetis Stock Underperforming the S&P 500?
Zoetis has significantly lagged the broader market over the past year, while analysts remain cautiously optimistic about its outlook.
Michael Burry Bought Beaten-Down Stocks And Shorted AI Favorites — Here’s How His August Bets Fared
The AI rally put Burry’s bearish stance under pressure as Palantir, CoreWeave, Oracle, Micron, Tesla, Nebius and Nvidia all climbed during August.
Phibro Animal Health Q4 Earnings Call Highlights
Phibro Animal Health (NASDAQ:PAHC) reported record fiscal 2026 sales and a sharp increase in adjusted EBITDA, supported by growth in its Animal Health and Mineral Nutrition businesses, the integration of its acquired Zoetis medicated feed additive portfolio, and operational initiatives under its Phi
Phibro Animal Health Corporation Q4 2026 Earnings Call Summary
Moby summary of Phibro Animal Health Corporation's Q4 2026 earnings call
Zoetis Wins Emergency Authorization for Simparica Trio, Can It Support a Slowing U.S. Business?
The timing of Zoetis Inc.’s (NYSE:ZTS) latest regulatory win is particularly relevant for shareholders. Just one week after the animal-health company reported a 7% decline in U.S. revenue and an 11% drop in domestic companion-animal product sales, Simparica Trio received Emergency Use Authorization to treat New World screwworm infestations in dogs and puppies. The treatment […]
Zoetis Earnings Reveal a Divided Business, But Can its Pipeline Restore Growth?
Zoetis Inc. (NYSE:ZTS) entered 2026 as a leader in animal health, but its latest earnings show that even a strong market position cannot fully insulate the company from weaker consumer demand. Fiscal Q2 2026 revenue remained flat at $2.5 billion and declined 1% on an organic operational basis, as pressure in the U.S. companion-animal market […]
3 of Wall Street’s Favorite Stocks We’re Skeptical Of
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Zoetis (ZTS) Stock Still Looks Cheap After a 62% Slide
Zoetis stock has had a tough run over the last few years, yet the current valuation checks suggest the shares may now be pricing in a lot of that bad news. After a prolonged slide, the question is whether the current market price properly reflects Zoetis' earnings power and risks. Over the past 5 years, Zoetis shareholders have seen the share price decline about 61.8%, which points to a significant reset in expectations. Recent investor focus is on how competition and softer pet care...
Is Zoetis’ Lowered 2026 Outlook and Simparica Trio EUA Altering The Investment Case For Zoetis (ZTS)?
Zoetis recently received an Emergency Use Authorization from the U.S. FDA for its Simparica Trio chewable to treat life-threatening New World screwworm infestations in dogs and puppies, while also appointing experienced healthcare executive Jay Saccaro as its new Chief Financial Officer and Chief Operating Officer. At the same time, Zoetis lowered its full-year 2026 revenue and earnings guidance, signaling a more cautious outlook even as it expands the clinical reach of one of its flagship...
Should You Continue to Retain PAHC Stock in Your Portfolio?
Phibro Animal Health's Animal Health growth and global reach support its outlook, but Brazil's antimicrobial transition and trade risks cloud near-term prospects.
Explore More Analysis for ZTS
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Zoetis Inc.
Zoetis Inc. (ZTS) is currently trading at $76.29. The RSI (14-day) is at 50.2, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $96.00 implies 25.8% upside from current levels. Volatility is moderate at 27.2% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Zoetis Inc. (ZTS): The trailing P/E ratio is 12.49, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 11.80, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 6.72, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 9.73. Price-to-Sales is 3.31. Valuation should be compared to Drug Manufacturers - Specialty & Generic industry peers for context, as different sectors trade at different multiples.
Based on 15 analysts covering ZTS, the consensus price target is $96.00. This represents a 25.8% upside from the current price of $76.29. The range spans from a low target of $80.00 to a high target of $155.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Zoetis Inc. (ZTS) pays a dividend with a current yield of approximately 2.78%. The annualized dividend rate is $2.06 per share. The payout ratio is 33.6%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-07-20T00:00:00.000Z.
Key risks for Zoetis Inc. (ZTS) investors include: 1. Moderate volatility (27.2% annualized)—price swings are notable. 2. Elevated debt levels (D/E ratio of 294.00) which could pressure margins in a rising rate environment. 3. Declining revenue (-20.0% YoY), indicating potential business headwinds. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Drug Manufacturers - Specialty & Generic sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Zoetis Inc.'s (ZTS) current debt and financial health profile: Total debt stands at $9.26B. The debt-to-equity ratio is 294.00, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 3.08, indicating strong short-term liquidity. The quick ratio is 1.57. The company holds $1.68B in cash and equivalents. Free cash flow is positive at $2.02B, providing a cushion for debt servicing and shareholder returns.